Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213025265> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4213025265 endingPage "80" @default.
- W4213025265 startingPage "80" @default.
- W4213025265 abstract "80 Background: Nine new treatments for mCRPC, each varying in efficacy and safety, have been approved over the last 10 years, changing the landscape of patient management. Understanding how patients perceive and value the efficacy, safety, and administration burden of these treatments can facilitate shared-decision making to determine optimal management. To our knowledge, this study is the first to elicit patient preferences for mCRPC treatments in the US. Methods: We conducted a cross-sectional survey using the discrete-choice experiment (DCE) method, in which participants were asked to state their choices over successive sets of treatment alternatives, defined by varying levels of treatment characteristics (i.e., attributes). Six treatment attributes in this DCE were examined: overall survival (OS), months until patients develop a fracture or bone metastasis, likelihood of requiring radiation to control bone pain, fatigue, nausea, and mode of administration. The levels taken by each of these attributes were selected to reflect clinical practice. Quota sampling was used in an online panel for recruitment to ensure that study sample is representative of the US prostate cancer population by age distribution. The choice responses were used to determine the value (i.e., preference weights) respondents placed on each attribute via the use of conditional and mixed logit models. The importance of attributes and marginal rates of substitutions were also calculated in order to understand how much patients were willing to trade off between different attributes. Results: The final dataset included 160 participants, with a mean age of 71.6 years old and a mean of 8.96 years since prostate cancer diagnosis. Participants noted their preferences for mCRPC treatments characteristics as follows (in decreasing order of importance over the attribute ranges included in the study): OS (relative attribute importance [RAI]: 31%), reduction in the need for bone pain control (23%), nausea (16%), months until patients develop a fracture or bone metastasis (15%), fatigue (11%), and mode of administration (3%). The marginal rates of substitution demonstrated that eliminating moderate nausea was perceived as equivalent to a 1.9-month reduction in OS, and a reduction of fatigue from severe to mild was perceived as equivalent to a reduction in OS of approximately 3.3 months. Conclusions: Improving OS remains the highest priority, but patients are willing to sacrifice some survival to avoid declines in quality of life, including avoiding bone pain/fracture, nausea, and fatigue, in the mCRPC disease state." @default.
- W4213025265 created "2022-02-24" @default.
- W4213025265 creator A5009847136 @default.
- W4213025265 creator A5012068187 @default.
- W4213025265 creator A5015111046 @default.
- W4213025265 creator A5047408345 @default.
- W4213025265 creator A5047494171 @default.
- W4213025265 creator A5076374306 @default.
- W4213025265 creator A5087184017 @default.
- W4213025265 date "2022-02-20" @default.
- W4213025265 modified "2023-10-18" @default.
- W4213025265 title "Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US survey." @default.
- W4213025265 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.080" @default.
- W4213025265 hasPublicationYear "2022" @default.
- W4213025265 type Work @default.
- W4213025265 citedByCount "0" @default.
- W4213025265 crossrefType "journal-article" @default.
- W4213025265 hasAuthorship W4213025265A5009847136 @default.
- W4213025265 hasAuthorship W4213025265A5012068187 @default.
- W4213025265 hasAuthorship W4213025265A5015111046 @default.
- W4213025265 hasAuthorship W4213025265A5047408345 @default.
- W4213025265 hasAuthorship W4213025265A5047494171 @default.
- W4213025265 hasAuthorship W4213025265A5076374306 @default.
- W4213025265 hasAuthorship W4213025265A5087184017 @default.
- W4213025265 hasConcept C105795698 @default.
- W4213025265 hasConcept C121608353 @default.
- W4213025265 hasConcept C126322002 @default.
- W4213025265 hasConcept C151956035 @default.
- W4213025265 hasConcept C2780192828 @default.
- W4213025265 hasConcept C2780580376 @default.
- W4213025265 hasConcept C2781249084 @default.
- W4213025265 hasConcept C2908647359 @default.
- W4213025265 hasConcept C33923547 @default.
- W4213025265 hasConcept C512399662 @default.
- W4213025265 hasConcept C71924100 @default.
- W4213025265 hasConcept C95057490 @default.
- W4213025265 hasConcept C99454951 @default.
- W4213025265 hasConceptScore W4213025265C105795698 @default.
- W4213025265 hasConceptScore W4213025265C121608353 @default.
- W4213025265 hasConceptScore W4213025265C126322002 @default.
- W4213025265 hasConceptScore W4213025265C151956035 @default.
- W4213025265 hasConceptScore W4213025265C2780192828 @default.
- W4213025265 hasConceptScore W4213025265C2780580376 @default.
- W4213025265 hasConceptScore W4213025265C2781249084 @default.
- W4213025265 hasConceptScore W4213025265C2908647359 @default.
- W4213025265 hasConceptScore W4213025265C33923547 @default.
- W4213025265 hasConceptScore W4213025265C512399662 @default.
- W4213025265 hasConceptScore W4213025265C71924100 @default.
- W4213025265 hasConceptScore W4213025265C95057490 @default.
- W4213025265 hasConceptScore W4213025265C99454951 @default.
- W4213025265 hasIssue "6_suppl" @default.
- W4213025265 hasLocation W42130252651 @default.
- W4213025265 hasOpenAccess W4213025265 @default.
- W4213025265 hasPrimaryLocation W42130252651 @default.
- W4213025265 hasRelatedWork W2083653180 @default.
- W4213025265 hasRelatedWork W2096612642 @default.
- W4213025265 hasRelatedWork W2363890076 @default.
- W4213025265 hasRelatedWork W2365364931 @default.
- W4213025265 hasRelatedWork W2383841506 @default.
- W4213025265 hasRelatedWork W2389709268 @default.
- W4213025265 hasRelatedWork W2418638721 @default.
- W4213025265 hasRelatedWork W2583958582 @default.
- W4213025265 hasRelatedWork W2893772422 @default.
- W4213025265 hasRelatedWork W4243514755 @default.
- W4213025265 hasVolume "40" @default.
- W4213025265 isParatext "false" @default.
- W4213025265 isRetracted "false" @default.
- W4213025265 workType "article" @default.